GENEVA (AP) — Swiss pharmaceutical giant Novartis AG defended a range of flu drugs that have been banned in Italy, while posting virtually flat third quarter profits as new drugs offset patent expirations.
The Basel-based company said Thursday it still had “confidence in the safety and efficacy of its seasonal influenza vaccines Agrippal and Fluad manufactured in Italy.”
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.